RedHill’s Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous …,

RedHill’s key clinical late-stage development programs include: (i) RHB-204, with an ongoing Phase 3 study for pulmonary nontuberculous …, RedHill’s key clinical late-stage development programs include: (i) RHB-204, with an ongoing Phase 3 study for pulmonary nontuberculous …, Read More

Scroll to Top